- View First CVGBM Glioblastoma Vaccine enters Phase 1 Trials Currently reading
Novel Drug & Emergent Therapeutics | Pharma | Rare Diseases | Neurology
Pre-Clinical Results Highlight Significant Promise for Novel mRNA Vaccine in Treating Glioblastoma
Time to read: 01:43 minutes
Originally published: 14 September 2024
Source: ESMO 2024 Abstracts
Type of article: Novel Drug & Emergent Therapy News
MedED Catalogue Reference: MNDR001
Category: Rare Diseases
Crossreference: Neurology
Category tags: glioblastoma, vaccine, mRNA
| Product Category | Product Name | Company | Status |
|---|---|---|---|
| Phase 1 Clinical Trial |
24 September 2024, ESMO Conference Post Presentation
CVGBM delivers an mRNA sequence with unmodified nucleotides encapsulated in lipid nanoparticles (LNPs), enabling targeted immune activation against glioblastoma cells.
The vaccine encodes a fusion protein comprising eight tumour-associated antigen (TAA)-derived epitopes, previously shown to elicit strong immune responses as peptide vaccines.
These encoded epitopes are presented on HLA-A*02:01 (HLA class I) or various HLA class II molecules, activating both CD8+ cytotoxic T cells and CD4+ helper T cells for a comprehensive anti-tumour response.
HLA class I molecules, such as HLA-A*02:01, present epitopes to CD8+ T cells, triggering the destruction of infected or abnormal cells.
Meanwhile, HLA class II molecules present epitopes to CD4+ T cells, which amplify the immune response by activating other immune cells, ensuring robust defence mechanisms.
Preclinical data presented earlier this year at ESMO confirmed the efficacy of CVGBM’s design. Vaccination in naïve CB6F1 mice elicited strong CD8+ and CD4+ T cell responses, validating the accurate translation and processing of the encoded fusion protein. Furthermore, a murine surrogate vaccine tested in tumour-bearing mice induced significant anti-tumour immune responses and extended survival.
These promising findings have supported the initiation of a Phase 1 clinical trial (CV-GBLM-001; NCT05938387) to evaluate CVGBM in HLA-A*02:01-positive patients with surgically resected, MGMT-unmethylated glioblastoma (CNS WHO Grade 4).
Clinical Trials & Supporting Information
| Clinical Study State | ClinicalTrial.gov Registration | Study Name |
|---|---|---|
Access Original Press Release
14 September 2024 | ESMO Abstracts| 22P - Pre-clinical development of CVGBM: A therapeutic mRNA-based multiepitope vaccine for glioblastoma
Disclaimer
This article is compiled from a variety of resources. Every effort has been made to correctly attribute quotes and content. Where possible all information has been independently verified. The Medical Education Network bears no responsibility for any inaccuracies which may occur from the use of third-party sources. If you have any queries regarding this article contact us
Fact-checking Policy
The Medical Education Network makes every effort to review and fact-check the articles used as source material in our summaries and original material. We have strict guidelines in relation to the publications we use as our source data, favouring peer-reviewed research wherever possible. Every effort is made to ensure that the information contained here is an accurate reflection of the original material. Should you find inaccuracies, out of date content or have any additional issues with our articles, please make use of the contact us form to notify us.
